Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Deupirfenidone · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Deupirfenidone | DRUG | size AA Swedish orange capsule |
| Pirfenidone (PFD) | DRUG | size AA Swedish orange capsule |
| Placebo | DRUG | placebo |
| Pirfenidone | DRUG | pirfenidone 801 mg TID |
Top 15 of 17 competitors
Deupirfenidone is an investigational small molecule being developed for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive scarring disease of the lungs. It is in Phase 3 clinical development and has not been approved for commercial use. PureTech Health plc is the developer.
Deupirfenidone is being developed by PureTech Health plc, which trades under the ticker PRTC. The company is advancing the asset through late-stage clinical testing in idiopathic pulmonary fibrosis, with a Phase 3 trial planned and a completed Phase 2 study in the same indication.
Deupirfenidone is in Phase 3 clinical development for idiopathic pulmonary fibrosis. Two trials are listed in the clinical registry: a Phase 3 study that is not yet recruiting and a Phase 2 study that is active but no longer recruiting. The drug remains investigational and has not been approved by the FDA.
Deupirfenidone is being studied in two registered trials. NCT07284602 is a Phase 3 trial evaluating its efficacy and safety compared to pirfenidone in adults with idiopathic pulmonary fibrosis, with an planned enrollment of 1,100 participants. NCT05321420 is a Phase 2 trial in patients with IPF that has completed enrollment and is active.
Yes. Deupirfenidone is also known by the development code LYT-100. Both names refer to the same investigational small molecule being developed by PureTech Health plc for idiopathic pulmonary fibrosis, so searches for either name point to the same clinical program.
Across the two registered trials, Deupirfenidone has a combined planned enrollment of approximately 1,340 participants. The Phase 3 trial NCT07284602 accounts for 1,100 of those participants, while the Phase 2 trial NCT05321420 accounts for 240. Both studies are in idiopathic pulmonary fibrosis.